Brimonidine in the treatment of glaucoma and ocular hypertension

References

• Collaborative Normal-Tension Glaucoma Study GroupComparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressuresAm J Ophthalmol1998126487979780093
   PubMed Web of Science ®Google Scholar
• The AGIS InvestigatorsThe Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deteriorationAm J Ophthalmol20001304294011024415
   PubMed Web of Science ®Google Scholar
• AcheampongAAShackletonMJohnBDistribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyesDrug Metab Dispos200230421911901096
   PubMed Web of Science ®Google Scholar
• AcheampongAAShackletonMTang-LiuDDComparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbitsDrug Metab Dispos199523708127587958
   PubMed Web of Science ®Google Scholar
• AungTOenFTWongHTRandomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closureBr J Ophthalmol200488889414693782
   PubMed Web of Science ®Google Scholar
• BerlinRJLeeUTSamplesJROphthalmic drops causing coma in an infantJ Pediatr2001138441311241061
   PubMed Web of Science ®Google Scholar
• CantorLBThe evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous useExpert Opin Pharmacother200018153411249518
   PubMedGoogle Scholar
• Carrasco FontCArias PuenteAGarcia SaenzMC[Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers]Arch Soc Esp Oftalmol200479163815124072
   PubMedGoogle Scholar
• ChoudhriSWandMShieldsMBA comparison of dorzolamide-timolol combination versus the concomitant drugsAm J Ophthalmol2000130832311124307
   PubMed Web of Science ®Google Scholar
• CravenERWaltersTRWilliamsRBrimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertensionJ Ocul Pharmacol Ther2005213374816117698
   PubMed Web of Science ®Google Scholar
• CvenkelBIhanAOcular surface changes induced by topical antiglaucoma monotherapyOphthalmologica2002216175912065853
   PubMed Web of Science ®Google Scholar
• DavidRBrimonidine (Alphagan): a clinical profile four years after launchEur J Ophthalmol200111Suppl 2S72711592536
   PubMed Web of Science ®Google Scholar
• DonelloJEPadilloEUWebsterMLalpha2-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemiaJ Pharmacol Exp Ther20012962162311123383
   PubMed Web of Science ®Google Scholar
• DongJQBabusisDMWeltyDFEffects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbitsJ Ocul Pharmacol Ther2004202859215321023
   PubMed Web of Science ®Google Scholar
• DranceSMGlaucoma: a look beyond intraocular pressureAm J Ophthalmol199712381799535626
   PubMed Web of Science ®Google Scholar
• FechtnerRDRealiniTFixed combinations of topical glaucoma medicationsCurr Opin Ophthalmol200415132515021225
   PubMedGoogle Scholar
• FerenczJRGiladyGHarelOTopical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularizationGraefes Arch Clin Exp Ophthalmol20052438778015785924
   PubMed Web of Science ®Google Scholar
• GõniFJBrimonidine–Timolol Fixed Combination Study Group12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertensionEur J Ophthalmol2005155819016167288
   PubMed Web of Science ®Google Scholar
• GrantRAjelloMVlassESalt water or high tech? A look at two new rinsing solutions for contact lensesOptician19962123841
   Google Scholar
• HedmanKAlmAA pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timololEur J Ophthalmol2000109510410887918
   PubMed Web of Science ®Google Scholar
• HeijlALeskeMCBengtssonBReduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma TrialArch Ophthalmol200212012687912365904
   PubMed Web of Science ®Google Scholar
• HigginbothamEJSchumanJSGoldbergIOne-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertensionArch Ophthalmol200212012869312365906
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol20021207011312049574
   PubMed Web of Science ®Google Scholar
• KatzLJBrimonidine Study GroupBrimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patientsAm J Ophthalmol19991272069932994
   PubMed Web of Science ®Google Scholar
• KatzLJBrimonidine–Purite Study Groups 1 and 2Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertensionJ Glaucoma2002111192611912359
   PubMed Web of Science ®Google Scholar
• KentARNussdorfJDDavidRVitreous concentration of topically applied brimonidine tartrate 0.2%Ophthalmology2001108784711297498
   PubMed Web of Science ®Google Scholar
• KleinBEKleinRSponselWEPrevalence of glaucoma. The Beaver Dam Eye StudyOphthalmology19929914995041454314
   PubMed Web of Science ®Google Scholar
• KonstasAGKarabatsasCHLallosN24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjectsOphthalmology2005112603815808251
   PubMed Web of Science ®Google Scholar
• LeBlancRPTwelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertensionOphthalmology1998105196079787370
   PubMed Web of Science ®Google Scholar
• LeeDAGornbeinJAbramsCThe effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trialJ Ocul Pharmacol Ther20001631810673126
   PubMed Web of Science ®Google Scholar
• LeeDAGornbeinJAEffectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trialJ Glaucoma200110220611442187
   PubMed Web of Science ®Google Scholar
• LeeDAHigginbothamEJGlaucoma and its treatment: a reviewAm J Health Syst Pharm200562691915790795
   PubMed Web of Science ®Google Scholar
• LeskeMCHeijlAHusseinMFactors for glaucoma progression and the effect of treatment: the early manifest glaucoma trialArch Ophthalmol2003121485612523884
   PubMed Web of Science ®Google Scholar
• LichterPRMuschDCGillespieBWInterim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgeryOphthalmology200110819435311713061
   PubMed Web of Science ®Google Scholar
• Mayor-TorroglosaSDe la VillaPRodriguezMEIschemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidineInvest Ophthalmol Vis Sci20054638253516186370
   PubMed Web of Science ®Google Scholar
• MelamedSDavidROngoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group IIClin Ther2000221031110688394
   PubMed Web of Science ®Google Scholar
• MorrisonJCElevated intraocular pressure and optic nerve injury models in the ratJ Glaucoma200514315715990616
   PubMed Web of Science ®Google Scholar
• NetlandPALandryTSullivanEKTravoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertensionAm J Ophthalmol20011324728411589866
   PubMed Web of Science ®Google Scholar
• NetlandPAMichaelMRosnerSABrimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertensionAdv Ther200320203012772815
   PubMed Web of Science ®Google Scholar
• NoeckerREffects of common ophthalmic preservatives on ocular healthAdv Ther2001182051511783457
   PubMed Web of Science ®Google Scholar
• NoeckerRJHerrygersLAAnwaruddinRCorneal and conjunctival changes caused by commonly used glaucoma medicationsCornea200423490615220734
   PubMed Web of Science ®Google Scholar
• OlthoffCMSchoutenJSvan de BorneBWNoncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. An evidence-based reviewOphthalmology20051129536115885795
   PubMed Web of Science ®Google Scholar
• OsborneNNChidlowGLaytonCJOptic nerve and neuroprotection strategiesEye20041810758415534592
   PubMed Web of Science ®Google Scholar
• ProkLHallDA 24-day old with episodic lethargy, hypotonia, and apnea: the eyes have itCurr Opin Pediatr200315226812640283
   PubMed Web of Science ®Google Scholar
• RasmussenCAKaufmanPLPrimate glaucoma modelsJ Glaucoma2005143111415990615
   PubMed Web of Science ®Google Scholar
• SallKNGreffLJJohnson-PrattLRDorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerabilityOphthalmology20031106152412623832
   PubMed Web of Science ®Google Scholar
• SchumanJSEffects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timololOphthalmology20001071171710857839
   PubMed Web of Science ®Google Scholar
• SchumanJSHorwitzBChoplinNTA 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trialArch Ophthalmol1997115847529230823
   PubMed Web of Science ®Google Scholar
• SharpeEDDayDGBeischelCJBrimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertensionBr J Ophthalmol200488953615205246
   PubMed Web of Science ®Google Scholar
• SimmonsSTEfficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertensionClin Ther2001236041911354394
   PubMed Web of Science ®Google Scholar
• SimmonsSTEarlMLThree-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure loweringOphthalmology200210930714 discussion 14–1511825814
   PubMed Web of Science ®Google Scholar
• SkutaGLParrishRK2ndWound healing in glaucoma filtering surgerySurv Ophthalmol198732149703328315
   PubMed Web of Science ®Google Scholar
• SleathBRobinALCovertDPatient-reported behavior and problems in using glaucoma medicationsOphthalmology2006113431616458967
   PubMed Web of Science ®Google Scholar
• SolishAMDeLuccaPTCasselDADorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measuresJ Glaucoma2004131495715097262
   PubMed Web of Science ®Google Scholar
• StewartWCSharpeEDHarbinTSJr.Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressureAm J Ophthalmol2000129723710926979
   PubMed Web of Science ®Google Scholar
• TaylorSAGalbraithSMMillsRPCauses of non-compliance with drug regimens in glaucoma patients: a qualitative studyJ Ocul Pharmacol Ther200218401912419091
   PubMed Web of Science ®Google Scholar
• TorisCBCamrasCBYablonskiMEAcute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patientsAm J Ophthalmol199912881410482088
   PubMed Web of Science ®Google Scholar
• TorisCBGleasonMLCamrasCBEffects of brimonidine on aqueous humor dynamics in human eyesArch Ophthalmol1995113151477487618
   PubMed Web of Science ®Google Scholar
• TsaiJCChangHWComparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked studyJ Ocul Pharmacol Ther2005214758216386089
   PubMed Web of Science ®Google Scholar
• Vidal-SanzMLafuenteMPMayor-TorroglosaSBrimonidine’s neuroprotective effects against transient ischaemia-induced retinal ganglion cell deathEur J Ophthalmol200111Suppl 2S364011592529
   PubMedGoogle Scholar
• WaltersTRDevelopment and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studiesSurv Ophthalmol199641Suppl 1S19268970246
   PubMed Web of Science ®Google Scholar
• WeinrebRNLevinLAIs neuroprotection a viable therapy for glaucoma?Arch Ophthalmol19991171540410565524
   PubMed Web of Science ®Google Scholar
• WhitsonJTHenryCHughesBComparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertensionJ Glaucoma2004131687315097265
   PubMed Web of Science ®Google Scholar
• WilhelmBLudtkeHWilhelmHEfficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trialGraefes Arch Clin Exp Ophthalmol2006244551816151785
   PubMed Web of Science ®Google Scholar
• WinfieldAJJessimanDWilliamsAA study of the causes of non-compliance by patients prescribed eyedropsBr J Ophthalmol199074477802390523
   PubMed Web of Science ®Google Scholar
• WoldeMussieERuizGWijonoMNeuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertensionInvest Ophthalmol Vis Sci20014228495511687528
   PubMed Web of Science ®Google Scholar
• YolesEWheelerLASchwartzMAlpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degenerationInvest Ophthalmol Vis Sci19994065739888428
   PubMed Web of Science ®Google Scholar
• ZabriskieNNetlandPAComparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trialsAdv Ther2003209210012836809
   PubMed Web of Science ®Google Scholar